Related by context. All words. (Click for frequent words.) 74 investigational humanized monoclonal antibody 72 oral prodrug 72 antibody MAb 71 novel VDA molecule 70 poly ADP ribose polymerase 70 MKC# MT 70 PEGylated anti 70 Phase 2b Clinical Trial 70 HGS ETR2 70 PEGylated Fab fragment 70 Archexin 69 Enzastaurin 69 dasatinib Sprycel ® 69 sunitinib Sutent ® 69 Ocrelizumab 69 essential thrombocythemia ET 69 Factor Receptor 69 selective modulator 69 IAP inhibitor 69 Kinase Inhibitor 69 irreversible inhibitor 69 orally administered inhibitor 69 Novel Oral 69 Personalized Immunotherapy 69 refractory chronic lymphocytic 69 NPC 1C 69 generation purine nucleoside 69 liposomal formulation 69 non nucleoside inhibitor 68 selectively inhibited 68 multi kinase inhibitor 68 mertansine 68 histone deacetylase HDAC inhibitor 68 soluble tumor necrosis 68 Gleevec resistant 68 Hsp# Inhibitor 68 androgen receptor AR 68 M2 subunit 68 sunitinib Sutent 68 AAG geldanamycin analog 68 Aflibercept 68 Epidermal Growth Factor Receptor 68 humanized interleukin 6 68 Factor VIIa 68 BiTE R 68 erlotinib Tarceva ® 68 Aplidin 68 histone deacetylase inhibitor 68 virus HCV protease inhibitor 68 HCV protease 68 Aurora Kinase 68 receptor tyrosine kinase inhibitor 68 targeted radiotherapeutic 68 Pralatrexate 68 protein tyrosine phosphatase 1B 68 FOLOTYN ® 68 AEG# 68 Ceflatonin 68 cetuximab Erbitux R 68 Panzem R 68 interleukin IL -# 68 vascular disrupting agent 68 Initiate Phase 68 Meets Primary Endpoint 68 DNA intercalator 68 Phase 2a Clinical Trial 68 R Saizen R 68 Achieves Primary Endpoint 68 IgG1 monoclonal antibody 68 mitogen activated ERK kinase 67 2 inhibitor CYT# 67 TNF Tumor Necrosis Factor 67 Irinotecan 67 Amrubicin 67 Protein Kinase C 67 Granulocyte Colony Stimulating Factor 67 Vandetanib 67 phosphate S1P 67 ALN HPN 67 humanized anti 67 humanized monoclonal 67 investigational monoclonal antibody 67 PNP inhibitor 67 Oral Fingolimod 67 JAK1 67 chemosensitizer 67 targeting CD# 67 radiation sensitizer 67 sodium glucose cotransporter 67 LymphoStat B belimumab 67 dasatinib Sprycel 67 Safinamide 67 colorectal carcinoma 67 proprietary polysaccharide 67 metastatic colorectal 67 trial evaluating PRX# 67 pathophysiological effects 67 CTAP# Capsules 67 Denufosol 67 imatinib Gleevec ® 67 Exherin TM 67 Peginterferon alfa 2b 67 Recombinant Human 67 myelodysplastic myeloproliferative diseases 67 PSMA ADC 67 regulated kinase 67 Janus kinase 67 MGd 67 myelofibrosis polycythemia vera 67 CYC# 67 pan HDAC inhibitor 67 IL# PE#QQR 67 CYT# potent vascular disrupting 67 Romiplostim 67 Solazed TM 67 Phase Ib clinical trials 67 NS#/#A protease 67 Vitaxin 67 pancreatic colon 67 Pivotal Phase 66 5 HT4 66 VEGF receptor 66 cytokines IL 66 K ras mutations 66 proteasome inhibitor 66 Immunotherapeutic 66 RON Notch 66 huC# DM4 66 generation antisense inhibitor 66 depsipeptide 66 immunotoxin 66 GMX# 66 Zorbtive TM 66 Annamycin 66 thetreatment 66 agonistic human 66 VitiGam 66 Evoltra ® 66 fosbretabulin 66 receptor inhibitor 66 MCSP respectively 66 AQ4N 66 mTOR mammalian target 66 EGFR HER2 66 GW# [003] 66 alpha folate receptor 66 alvespimycin 66 Androgen Receptor 66 sorafenib tablets 66 chemokine receptor 66 ribonucleotide reductase clinically validated 66 selective kinase inhibitor 66 Degarelix 66 MAGE A3 ASCI 66 luteinizing hormone releasing 66 Phase #b/#a clinical 66 seliciclib CYC# 66 selective inhibition 66 leukocyte adhesion 66 receptor inhibiting monoclonal 66 c Raf kinase 66 Insegia 66 reversible inhibitor 66 Receives Orphan Drug Designation 66 docetaxel Taxotere ® 66 isoform selective 66 bevacizumab Avastin ® 66 corticosteroid dexamethasone 66 RNAi therapeutic targeting 66 phosphatidylinositol 3 66 Kit CD# positive 66 mapatumumab 66 RNAi Therapeutic 66 sphingosine 1 66 humanized monoclonal antibodies 66 HuLuc# 66 Liposomal 66 Panzem NCD 66 immunostimulatory 66 FGFR 66 humanized monoclonal antibody 66 Adjuvant Treatment 66 Cytotoxic T 66 Daclizumab 66 induced macular edema 66 drug conjugate 66 Presents Preclinical Data 66 CD# antibody [001] 66 murine model 66 Combination REOLYSIN R 66 tiuxetan 66 recurrent glioblastoma multiforme 66 peptidic compound 66 NS4A 66 Randomized Phase 66 pralatrexate injection folate analogue 66 apoptosis proteins 66 Luteinizing Hormone Releasing Hormone 66 Tezampanel 66 cell adhesion molecule 66 HDAC Inhibitor 66 tumors GIST 66 CYP#A# CYP#D# 66 Tumour Vascular Disrupting Agent 66 Metastatic Melanoma 66 Preclinical studies suggest 66 CA4P 65 Onconase 65 potently inhibited 65 IMC #B 65 Upregulation 65 Initiates Phase II 65 mGluR5 negative 65 HER1 65 sorafenib Nexavar 65 selective agonist 65 Completes Patient Enrollment 65 Trial Evaluating 65 CD4 monoclonal antibody 65 Fc fusion protein 65 RhuDex R 65 accumulate preferentially 65 chronic eosinophilic leukemia 65 Tumor necrosis factor 65 Deforolimus 65 compound AEZS 65 vapreotide acetate 65 Blinatumomab 65 demonstrated antitumor activity 65 Bezielle 65 cytotoxic effects 65 downregulates 65 CD# CEA 65 Antitumor Activity 65 targeted antifolate 65 polycythemia vera essential thrombocythemia 65 castrate resistant prostate cancer 65 adecatumumab MT# 65 methylnaltrexone bromide 65 ARRY # 65 induces apoptosis 65 LymphoStat B TM 65 N acetylgalactosamine 6 65 antisense oligonucleotide 65 TRO# 65 Seliciclib 65 mediated apoptosis 65 cyclin dependent kinase inhibitor 65 Pivotal Phase III 65 nucleoside analog 65 Aplidin R 65 polysaccharide polymer 65 Tumor Necrosis Factor 65 alkylating agent 65 DAVANAT 65 GVAX ® 65 NS5b 65 Successfully Completes Phase 65 dependent kinase inhibitor 65 Azacitidine 65 IMA# 65 metastatic pancreatic 65 R roscovitine CDK cyclin 65 triggers apoptosis programmed 65 systemic anaplastic large 65 epithelial tumors 65 tyrosine kinase receptor 65 Hormone Refractory Prostate Cancer 65 trastuzumab Herceptin R 65 abnormal p# 65 cetuximab Erbitux 65 Nexavar ® 65 vaccine GRNVAC1 65 Thiovir 65 specific lectin receptors 65 small molecule tyrosine 65 Orally administered 65 PKC# 65 APOPTONE 65 BZL# 65 zanolimumab 65 mu opioid receptor antagonist 65 2 methoxyestradiol 65 cisplatin resistant 65 polycythemia vera PV 65 RANK Ligand 65 antiproliferative effects 65 colon carcinoma 65 NeoLipid R 65 Trastuzumab DM1 65 HGS ETR1 65 malignant ascites 65 5 HT6 receptor 65 GRN#L 65 pediatric acute lymphoblastic 65 VEGFR2 inhibitor 65 antibody blinatumomab MT#/MEDI-# 65 CD# monoclonal antibody 65 CDK inhibitor 65 acetylcholinesterase AChE 65 allosteric modulator NAM 65 PEG SN# 65 MyVax R 65 monoclonal anti 65 Preclinical Study 65 sarcoma melanoma 65 acid phosphatase PAP 65 molecule epidermal 65 bevacizumab Avastin R 65 diarrhea predominant irritable 65 YONDELIS 65 Clusterin 65 Azedra 65 potently inhibit 65 MT#/MEDI-# 65 Golimumab 65 hypereosinophilic syndrome 64 mGluR2 NAM 64 RAV# 64 binds selectively 64 RhuDex TM 64 partial agonist 64 TLR9 agonist 64 JAK2 inhibitor 64 Reports Preclinical Data 64 HGS ETR1 mapatumumab 64 Kinoid 64 Pharmacokinetics PK 64 thalidomide Thalomid 64 Hypoxia Inducible Factor 64 Cloretazine ® 64 SPRYCEL ® 64 LHRH receptor positive 64 factor HGF 64 PANVAC VF 64 telomerase inhibitor drug 64 interferon gamma 1b 64 Xanafide 64 refractory acute myeloid 64 SGLT2 64 Milatuzumab 64 potent inhibitor 64 PDX pralatrexate 64 inducible nitric oxide synthase 64 NS5B polymerase 64 negative allosteric modulator 64 sapropterin dihydrochloride 64 Initiate Clinical Trial 64 Tyrosine Kinase Inhibitor 64 kidney urologic 64 Phase 2b Trial 64 leukemia AML 64 investigational immunotherapy 64 OMP #R# 64 5 fluorouracil leucovorin 64 Glufosfamide 64 beta 1a 64 delay bone metastases 64 Vidofludimus 64 Omacetaxine 64 Serostim R 64 Diffuse Large B 64 BRAF mutant 64 CCR2 64 CDK cyclin dependent 64 Advanced Renal Cell 64 Vascular Disrupting Agent 64 Panzem R NCD 64 Vicinium TM 64 multiple myeloma MM 64 Announces Poster Presentations 64 Proxinium TM 64 bladder ovarian 64 registrational trial 64 Squalamine 64 IMC A# 64 Clevudine 64 cyclooxygenase COX 64 selective androgen receptor modulator 64 lexidronam injection 64 Cetrorelix 64 anti CD3 64 protein secreted 64 selective antagonist 64 EGFR TKI 64 Oral Formulation 64 PDE4 inhibitor 64 IAP inhibitors 64 PROSTASCINT R 64 glucagon receptor 64 Sudhir Agrawal D.Phil 64 metastatic malignant 64 trastuzumab DM1 64 HER2 HER2 64 p# mitogen activated 64 syngeneic 64 Signaling Pathway 64 HyperAcute 64 acetonide FA 64 Tie2 64 Bosutinib 64 intratumoral injection 64 Sapacitabine 64 MKC# MKC# PP 64 HIF 1α 64 thrombin receptor 64 Angiotensin II 64 huN# DM1 64 investigational oral inhibitor 64 LEP ETU 64 monocytes macrophages 64 transthyretin TTR mediated amyloidosis 64 Angiotensin Converting Enzyme 64 SAR# [004] 64 refractory cutaneous T 64 matrix metalloproteinases MMPs 64 Civacir 64 Adenosine A2A 64 factor G CSF 64 HuMax CD4 64 methionine aminopeptidase 64 vinca alkaloid 64 orally bioavailable 64 HCV NS5B polymerase 64 YONDELIS R 64 SGLT 64 modified glutathione analog 64 ® lenalidomide 64 highly selective inhibitor 64 ABLYNX 64 Phase III Pivotal 64 oncolytic virus therapies 64 receptor CXCR4 64 gefitinib Iressa 64 Zarnestra 64 anticancer compound 64 A3 adenosine receptor 64 Apaziquone 64 XL# anticancer compounds 64 receptor partial agonist 64 mitogenic 64 Silodosin 64 cMET 64 OXi# 64 mda 7 64 Mucosal 64 Temsirolimus 64 vesicular monoamine transporter 64 cutaneous T 64 AT1R 64 Endothelin 64 Antigen Specific 64 telomerase inhibitor 64 adalimumab Humira 64 PI3K/mTOR 64 Methylnaltrexone 64 CEQ# 64 Aurora kinase 64 mGluR5 NAM 64 telomerase therapeutic 64 Epratuzumab 64 Cloretazine 64 candidates Azedra TM 64 Antitumor activity 64 Voreloxin 64 Zybrestat 64 Genentech Rituxan 64 BCG refractory carcinoma 64 entinostat 64 ganetespib 64 Initiates Phase 64 evaluating tivozanib 64 Presents Preclinical 64 anti CD# monoclonal 64 #beta HSD1 64 gemcitabine Gemzar ® 64 monoclonal antibody IgG1 Mab 64 ocular formulation 64 inhibitor RG# 64 Relapsed Refractory 64 Ecallantide 64 BRIM2 64 antiangiogenic agent 64 Interferon gamma 64 hormone LHRH antagonist 64 including eniluracil ADH 64 compound perifosine 64 Ep CAM 64 Curaxin CBLC# 64 Bafetinib 64 HuMax EGFr 64 phase IIb clinical 64 novel emulsion formulation 64 small molecule thrombopoietin 64 topoisomerase II inhibitor 63 HIF 1alpha 63 Drug Candidate 63 EndoTAG 63 Induces Apoptosis 63 Begins Dosing 63 oral proteasome inhibitor 63 novel tubulin binding 63 Factor VEGF 63 Dapagliflozin 63 ALN PCS 63 ON #.Na 63 hypoxia inducible factor 63 IMiDs R 63 tumor xenograft models 63 Alfacell proprietary ribonuclease 63 Phase III Clinical Trial 63 RNA antagonist 63 antisense inhibitors 63 mediated inhibition 63 cytoprotective 63 c MET 63 5 HT2A serotonin 63 related apoptosis inducing 63 Granted Orphan Drug 63 Virulizin ® 63 vidofludimus 63 ixabepilone 63 cyclin dependent kinases CDKs 63 Randomized Phase II 63 TO AVOID PREGNANCY WHILE 63 Trofex 63 TNFalpha 63 TKB# 63 TACI Ig 63 TRX1 63 angiogenesis inhibitor 63 evaluating picoplatin 63 EpCAM 63 selective inhibitor 63 Akt inhibitor 63 Glucagon Like Peptide 63 TTR gene 63 polymerase inhibitor 63 ara C 63 Clolar ® 63 glycogen synthase kinase 63 initiated Phase Ib 63 Neulasta ® 63 HCD# [002] 63 pertuzumab 63 HSP# inhibitor 63 octreotide implant 63 aurora kinase 63 mTOR inhibitor 63 AVE# 63 tyrosine kinase inhibitor 63 Natalizumab 63 PD LID 63 5 HT2A receptor 63 Lymphocytic 63 Epothilone D 63 Ovitrelle R Serostim 63 R lenalidomide 63 phase IIb trial 63 selective immunoproteasome inhibitor 63 Yondelis ® 63 HER2 positive metastatic breast 63 ruxolitinib 63 cytotoxin 63 serine threonine 63 Nexavar sorafenib 63 Gleevec imatinib mesylate 63 vorinostat 63 Ad5FGF 4 63 apoptosis induced 63 BiTE ® 63 Humanized Anti 63 Cutaneous T 63 eIF 4E 63 estramustine 63 aplastic anemia AA 63 familial amyloidotic polyneuropathy FAP 63 Quinamed 63 ligand TRAIL 63 prostate cancer AIPC 63 TRAIL R2 63 metastatic castration resistant 63 receptor monoclonal antibody 63 D aspartate NMDA receptor 63 brivanib 63 docetaxel Taxotere R 63 Zemiva TM 63 anti angiogenic agent 63 Files IND 63 EGFR tyrosine kinase inhibitor 63 Trofex TM 63 Ceflatonin R 63 Study Evaluating 63 Serostim ® 63 alpha antagonist 63 Initiates Clinical 63 Torisel temsirolimus 63 Phase 2a Trial 63 AVASTIN 63 1beta 63 EndoTAG TM -1 63 Rigel R# 63 XL# inhibits 63 CRMD# 63 lymphoid organs 63 dopamine D2 63 pharmacological chaperone 63 humanised monoclonal antibody 63 Late Breaker 63 potent antiproliferative 63 immunomodulating 63 autologous cellular immunotherapy 63 ALN TTR 63 histone deacetylase HDAC 63 cytotoxic T lymphocyte 63 ® decitabine 63 Neulasta R 63 Wafer polifeprosan 63 Telatinib 63 Prolongs Survival 63 Vascular Endothelial Growth 63 lysophosphatidic acid LPA 63 selectively inhibiting 63 monoclonal antibody MAb 63 hypoxia activated prodrug 63 adult mesenchymal stem 63 Aliskiren 63 Î ² 63 cell lymphoma CTCL 63 IgG1 antibody 63 small molecule agonists 63 treat benign prostatic 63 inverse agonist 63 CCX# B 63 fallopian tube cancers 63 humanized antibody 63 occlusion PAO 63 gemcitabine Gemzar 63 metastatic hormone refractory 63 CD3 monoclonal antibody 63 IN PATIENTS WITH 63 pan histone deacetylase 63 FLT3 63 oral JAK1 63 Interferon alpha 63 Anti Tumor 63 Ofatumumab 63 Neuvenge 63 plus dacarbazine 63 Vidaza azacitidine 63 Raf kinase 63 Romidepsin 63 chronic thromboembolic pulmonary 63 FOLFOX6 63 cortisol synthesis 63 lintuzumab SGN 63 small molecule Hedgehog 63 Phase IIb Trial 63 GVAX R 63 peptibody 63 C1 esterase inhibitor 63 carcinoembryonic antigen 63 vinorelbine tartrate 63 Carfilzomib 63 metastatic neuroendocrine tumors 63 ERK1 2 63 hormone LHRH 63 imatinib Gleevec 63 Refractory Hodgkin Lymphoma 63 Dendritic Cells 63 oral ridaforolimus 63 riociguat 63 PKC inhibitor 63 CCR9 63 LHRH antagonists 63 AKT inhibitor 63 Seliciclib CYC# 63 dihydrochloride Tablets 63 5 HT6 63 INSPIRE Trial Phase III 63 metastatic castrate resistant 63 Marqibo TM 63 Viprovex R 63 potent inducer 63 rALLy clinical trial 63 Oncolytic 63 Preclinical studies 63 PTP 1B 63 Novel Small Molecule 63 seliciclib 63 novel histone deacetylase 63 anti PlGF 63 Vicriviroc 63 Therapeutic Vaccine 63 PSN# [002] 63 PLK1 SNALP 63 PDGFR B 63 sodium thiosulfate STS 63 intercellular adhesion molecule 63 Ixempra 63 Homspera TM 63 dose escalation clinical 63 metabotropic glutamate receptor 63 milatuzumab 63 Progenitor Cells 63 AMPA kainate 63 Chemophase 63 dihydrochloride 63 Elvitegravir 63 investigational pan BCR 63 Pirfenidone 63 Bavituximab 63 Clinical Trial Results 63 Corgentin 63 Pemetrexed 63 HuMax 63 retinoic acid receptor 63 Ozarelix 63 Ambrisentan 63 RANK Ligand inhibitor 63 Sphingomab TM 63 small molecule activator 63 advanced metastatic renal 63 PF # [002] 63 relapsed multiple myeloma 63 TBC# 63 First Patient Dosed 63 CD# expressing 63 histone deacetylase 63 EZN 63 formerly LymphoStat B 63 mouse xenograft models 63 Vidaza ® 63 DPX Survivac 63 Pivotal Study 63 Onalta 63 R sorafenib tablets 63 PRT# 63 Allovectin 7 63 anticancer agent 63 Kamada AAT 63 RhuDex ® 63 dextromethorphan quinidine 63 novel peptide 62 Telik logo TELINTRA 62 Bortezomib 62 ENMD # 62 NU# direct 62 Patients Treated With 62 Commence Phase 62 Janus Kinase 62 Pathway Inhibitor 62 EGFr expressing metastatic colorectal 62 gastrointestinal stromal tumors GIST 62 Camptosar ® irinotecan 62 Intravenous Human 62 5 HT4 receptor 62 Interferon Beta 62 Darinaparsin 62 receptor blocker 62 EOquin TM 62 Parathyroid Hormone 62 Varespladib 62 targets Galectin receptors 62 5 FU leucovorin 62 signal transduction inhibitors 62 PDGF receptor 62 NV1FGF 62 epothilones 62 antibody trastuzumab 62 CCX# 62 Genasense ® 62 OMP #M# 62 thromboxane A2 62 monocyte chemotactic protein 62 kallikrein 62 Tarceva TM 62 triggers apoptosis 62 complement inhibitor eculizumab 62 Topoisomerase II 62 thymidine kinase 62 therapeutic monoclonal antibody 62 CCR9 antagonist 62 GRN# 62 multicenter Phase II 62 leukemia CLL 62 SSc 62 CBLC# 62 Cannabinor 62 neratinib 62 Xyfid TM 62 Akt activation 62 human IgG1 monoclonal 62 Camptosar ® 62 tubulin inhibitor 62 cytolytic 62 TRAIL induced apoptosis 62 Micromet BiTE 62 plasma kallikrein inhibitor 62 LHRH antagonist 62 G#DT 62 chimeric monoclonal antibody 62 oral ghrelin agonist 62 oral picoplatin 62 Familial Adenomatous Polyposis FAP 62 investigational oral hepatitis C 62 apoptosis inducer 62 monoclonal antibody conjugated 62 Platelet Derived Growth 62 ELACYT 62 potent topoisomerase II 62 volociximab 62 Lubiprostone 62 somatostatin analogue 62 Tanespimycin 62 KSP inhibitor 62 Vaprisol 62 IGF IR 62 Aurora kinase inhibitor 62 Thiarabine 62 Dose Escalation 62 5 Fluorouracil 62 nilotinib Tasigna ® 62 heparanase 62 N methyl 62 NTDDS 62 Prednisone Against Refractory 62 MT# MEDI 62 orthotopic model 62 evaluating T DM1 62 reslizumab 62 RAS MAPK pathway 62 Novel Mechanism 62 HDL Selective Delipidation 62 SNT MC# 62 alpha#beta# 62 preclinically 62 adecatumumab 62 Ostarine ™ 62 Antisense Oligonucleotides 62 IGF1R 62 Parkinson disease levodopa induced 62 microsphere therapy 62 inhibit angiogenesis 62 Stromal 62 HDACi 62 PI3 kinase inhibitors 62 Fibroblast Growth Factor Receptor 62 bispecific 62 Panitumumab 62 hyaluronidase enzyme 62 XYOTAX TM 62 thymalfasin 62 Copegus ribavirin 62 p# MAPK 62 chemopreventive agent 62 investigational hepatitis C 62 II Clinical Trial 62 HCV RNA polymerase 62 demethylating agent 62 humanised antibody 62 Xcytrin R 62 Troxatyl 62 catheter occlusion 62 mTOR inhibition 62 RAF kinase VEGFR 62 Cdc7 62 transthyretin TTR 62 Fx #A 62 metastatic colorectal carcinoma 62 potently inhibits 62 Submits IND 62 Cell Lymphoma 62 GTC recombinant human 62 T#I [002] 62 Receptor Antagonist 62 chemoresistant 62 TRAIL Receptor 62 metaglidasen 62 LUX Lung 62 TroVax ® 62 motesanib 62 systemic RNAi therapeutic 62 Presents Positive 62 alfa 2a 62 Dasatinib 62 antisense inhibitor 62 CCR1 62 gastrin 62 Receptor Agonist 62 Tyrima 62 VEGFR1 62 Lenalidomide 62 Efficacy Results 62 Sym# 62 Nedd4 62 casein kinase 62 forodesine 62 BENLYSTA ® 62 lumiliximab 62 mediate antibody 62 coronary vasodilation 62 Spiegelmer ® 62 molecular imaging radiopharmaceutical 62 OncoVex 62 Perifosine 62 sunitinib malate 62 Initiates Phase III 62 Angiolix R 62 Initiates Enrollment 62 gemcitabine cisplatin 62 Grb 2 62 R bendamustine hydrochloride 62 mitogen activated protein 62 Secretase 62 E#F# 62 denileukin diftitox 62 Cytochrome P# 62 oral deforolimus 62 cutaneous T cell 62 TGF alpha 62 Eg5 62 factor TNF 62 P#X# antagonist 62 including HGF ErbB3 62 INS# [001] 62 BAL# [001] 62 folate receptor 62 SinuNase ™ 62 ZYBRESTAT TM 62 Onalta ™ 62 Hematological Malignancies 62 oral kinase inhibitor 62 Ixabepilone 62 Preclinical Data 62 novel synthetic PEGylated 62 FDA Accepts 62 iobenguane 62 Cyclooxygenase Inhibiting Nitric Oxide 62 alpha TNF 62 Tesetaxel 62 DNA hypermethylation 62 CORT # 62 ZOLINZA 62 interferon beta 1a infertility 62 Phase IIb clinical trials 62 peripherally acting 62 Bazedoxifene 62 platform HDL Mimetic 62 compound PMX # 62 TLK# 62 anionic backbone 62 multikinase inhibitor 62 oral Hsp# inhibitor 62 TRAIL receptor 62 BRAF inhibitor 62 tiapamil 62 JAK inhibitor 62 EGF receptor 62 2A receptor agonist 62 Immunohistochemical analysis 62 FDA APPROVES 62 hematological cancers 62 S#P# 62 INCB# [003] 62 selective inverse agonist 62 ERBITUX cetuximab 62 opioid induced bowel dysfunction 62 Maribavir 62 retaspimycin hydrochloride 62 MKC# 62 anaplastic lymphoma kinase ALK 62 GLP toxicology studies 62 Lenocta TM 62 mRCC 62 Fludara ® 62 calcitonin gene related 62 Breast Cancer Assay 62 PEG IFN 62 mTOR kinase 62 IRX 2 62 Phase IIa Clinical Trial 62 Talabostat 62 Friedreich Ataxia FRDA 62 gastro intestinal inflammation 62 androgen independent 62 ADAMTS# 62 Phase 2b Study 62 Initiates Clinical Trial 62 Afatinib 62 HCV NS3 protease 62 PXD# 62 oral Azacitidine 62 anti amnesic 62 ADP receptor antagonist 62 #HT#A 62 BAL# [002] 62 OvaRex R 62 endothelin receptor